CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK5 inhibitors(Cyclin-dependent kinase 5 inhibitors), CDK7 gene inhibitors(Cyclin-dependent kinase 7 gene inhibitors)

Therapeutic Areas

NeoplasmsNervous System Diseases

Active Indication

High grade gliomaRecurrent Glioma

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Hepatocellular Carcinoma+ [8]

Originator Organization

SynCore Biotechnology Co., Ltd.

Active Organization

Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.

Beijing Percans Oncology Co., Ltd.

Inactive Organization

Adastra Pharmaceuticals, Inc.

National Cancer Institute

Lee's Pharmaceutical Holdings Ltd.

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC29H32N4O8

InChIKeyNWYDRHSNEATNRI-SQQVDAMQSA-N

CAS Registry1204918-73-9

Clinical Trials associated with Zotiraciclib

NCT05588141 / RecruitingPhase 1/2IIT

A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Background:
Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
Objective:
To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.
Eligibility:
People aged 18 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 genes.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have an MRI of their brain. A new biopsy may be needed if previous results are not available.
Zotiraciclib is a capsule taken by mouth with a glass of water. Participants will take the drug at home on days 1, 4, 8, 11, 15, and 18 of a 28-day cycle. They may also be given medications to prevent side effects of the study drug. The schedule for taking the study drug may vary for participants who will undergo surgery.
Participants will be given a medication diary for each cycle. They will write down the date and time of each dose of the study drug.
Participants will visit the clinic about once a month. They will have a physical exam, blood tests, and tests to evaluate their heart function. An MRI of the brain will be repeated every 8 weeks.
Participants may remain in the study for up to 18 cycles (1.5 years).
...

Start Date16 May 2023

Sponsor / Collaborator

National Cancer Institute

CTR20182002 / RecruitingPhase 1

口服TG02胶囊治疗TMZ治疗失败的复发/进展性高级别脑胶质瘤患者单中心、剂量递增、开放I期临床研究

[Translation] A single-center, dose-escalation, open-label phase I clinical study of oral TG02 capsules in patients with recurrent/progressive high-grade glioma who have failed TMZ treatment

主要目标：探索剂量限制性毒性（DLT）和最大耐受剂量（MTD）次要目标：1、评估研究药物的药代动力学参数；2、评估研究药物的心脏安全性；3、初步评估研究药物抗肿瘤的有效性。探索性目标：探索肿瘤组织myc和mcl-1表达与临床疗效的关系。

[Translation]

Primary objective: To explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) Secondary objectives: 1. To evaluate the pharmacokinetic parameters of the study drug; 2. To evaluate the cardiac safety of the study drug; 3. To preliminarily evaluate the anti-tumor effectiveness of the study drug. Exploratory objective: To explore the relationship between the expression of MYC and MCL-1 in tumor tissue and clinical efficacy.

Start Date24 Apr 2019

Sponsor / Collaborator

Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.

NCT03904628 / Unknown statusPhase 1

Single-center, Dose Escalation, Open Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients With Failed TMZ Treatment

The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.

Start Date22 Mar 2019

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

100 Clinical Results associated with Zotiraciclib

100 Translational Medicine associated with Zotiraciclib

100 Patents (Medical) associated with Zotiraciclib

Literatures (Medical) associated with Zotiraciclib

01 Feb 2024·European journal of cancer (Oxford, England : 1990)

Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial

Article

Author: Le Rhun, Emilie ; Roth, Patrick ; Cartalat, Stephanie ; Ducray, François ; Gorlia, Thierry ; Gramatzki, Dorothee ; van den Bent, Martin ; Chinot, Olivier L ; Hau, Peter ; Maurage, Claude-Alain ; Furtner, Julia ; Reifenberger, Guido ; Weller, Michael ; Collienne, Maike ; Preusser, Matthias ; Jongen, Joost ; Felsberg, Jörg

BACKGROUND:

Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently overexpressed in glioblastoma.

METHODS:

EORTC 1608 (NCT03224104) (STEAM) had a three parallel group (A,B,C) phase Ib, open-label, non-randomized, multicenter design in IDH wild-type newly diagnosed glioblastoma or anaplastic astrocytoma. Groups A and B explored the maximum tolerated dose (MTD) of TG02 in elderly patients, in combination with hypofractionated radiotherapy alone (group A) or temozolomide alone (group B), according to O⁶-methylguanine DNA methyltransferase promoter methylation status determined centrally. Group C explored single agent activity of TG02 at first relapse after temozolomide chemoradiotherapy with a primary endpoint of progression-free survival at 6 months (PFS-6). Tumor expression of CDK-9, c-MYC and MCL-1 was determined by immunohistochemistry.

RESULTS:

The MTD was 150 mg twice weekly in combination with radiotherapy alone (group A) or temozolomide alone (group B). Two dose-limiting toxicities were observed at 150 mg: one in group A (grade 3 seizure), one in group B (multiple grade 1 events). Main toxicities included neutropenia, gastrointestinal disorders and hepatotoxicity. PFS-6 in group C was 6.7%. CDK-9, c-MYC and MCL-1 were confirmed to be expressed and their expression was moderately cross-correlated. High protein levels of MCL-1 were associated with inferior survival.

CONCLUSIONS:

TG02 exhibits overlapping toxicity with alkylating agents and low single agent clinical activity in recurrent glioblastoma. The role of CDK-9 and its down-stream effectors as prognostic factors and therapeutic targets in glioblastoma warrants further study.

01 Jan 2023·Current cancer drug targets

An Overview of CDK Enzyme Inhibitors in Cancer Therapy.

Article

Author: Kumar, Honnavalli Yogish ; Namitha, Bannimath ; Mounika, Peddaguravagari ; Gurupadayya, Bannimath

The ability to address the cell cycle in cancer therapy brings up new medication development possibilities. Cyclin-dependent kinases are a group of proteins that control the progression of the cell cycle. The CDK/cyclin complexes are activated when specific CDK sites are phosphorylated. Because of their non-selectivity and severe toxicity, most first-generation CDK inhibitors (also known as pan-CDK inhibitors) have not been authorized for clinical usage. Despite this, significant progress has been made in allowing pan-CDK inhibitors to be employed in clinical settings. Pan-CDK inhibitors' toxicity and side effects have been lowered in recent years because of the introduction of combination therapy techniques. As a result of this, pan-CDK inhibitors have regained a lot of clinical potential as a combination therapy approach. The CDK family members have been introduced in this overview, and their important roles in cell cycle control have been discussed. Then, we have described the current state of CDK inhibitor research, with a focus on inhibitors other than CDK4/6. We have mentioned first-generation pan-CDKIs, flavopiridol and roscovitine, as well as second-generation CDKIs, dinaciclib, P276-00, AT7519, TG02, roniciclib, and RGB-286638, based on their research phases, clinical trials, and cancer targeting. CDKIs are CDK4/6, CDK7, CDK9, and CDK12 inhibitors. Finally, we have looked into the efficacy of CDK inhibitors and PD1/PDL1 antibodies when used together, which could lead to the development of a viable cancer treatment strategy.

01 Dec 2021·Journal of neurosurgery. PediatricsQ3 · MEDICINE

Targeting of cyclin-dependent kinases in atypical teratoid rhabdoid tumors with multikinase inhibitor TG02

Q3 · MEDICINE

Article

Author: Brem, Henry ; Casaos, Joshua ; Huq, Sakibul ; Ding, Andy S. ; Pant, Ayush ; Zhao, Tianna ; Srivastava, Siddhartha ; Serra, Riccardo ; Raj, Divyaansh ; Tyler, Betty ; Kim, Timothy ; Gorelick, Noah L. ; Morales, Manuel

OBJECTIVE:

Atypical teratoid rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors with no current standard of care and an estimated median patient survival of 12 to 18 months. Previous genetic analyses have implicated cyclin D1 and enhancer of zeste homolog 2 (EZH2), a histone methyltransferase that is implicated in many cancers, as key drivers of tumorigenicity in ATRTs. Since the effects of EZH2 and cyclin D1 are facilitated by a host of cyclin-dependent kinases (CDKs), the authors sought to investigate the potential therapeutic effects of targeting CDKs in ATRTs with the multi–CDK inhibitor, TG02.

METHODS:

Human ATRT cell lines BT12, BT37, CHLA05, and CHLA06 were selected for investigation. The effects of TG02 on cell viability, proliferation, clonogenicity, and apoptosis were assessed via Cell Counting Kit-8 assays, cell counting, clonogenic assays, and flow cytometry, respectively. Similar methods were used to determine the effects of TG02 combined with radiation therapy (RT) or cisplatin. Synergism indices for TG02-cisplatin combination therapy were calculated using CompuSyn software.

RESULTS:

TG02 was observed to significantly impair ATRT cell growth in vitro by limiting cell proliferation and clonogenicity, and by inducing apoptosis. TG02 inhibited ATRT cell proliferation and decreased cell viability in a dose-dependent manner with nanomolar half maximal effective concentration (EC50) values (BT12, 207.0 nM; BT37, 127.8 nM; CHLA05, 29.7 nM; CHLA06, 18.7 nM). TG02 (150 nM) dramatically increased the proportion of apoptotic ATRT cells 72 hours posttreatment (TG02 8.50% vs control 1.52% apoptotic cells in BT12, p < 0.0001; TG02 70.07% vs control 15.36%, p < 0.0001). Combination therapy studies revealed that TG02 acted as a potent radiosensitizer in ATRT cells (BT12 surviving fraction, RT 51.2% vs RT + TG02 21.7%). Finally, CompuSyn analysis demonstrated that TG02 acted synergistically with cisplatin against ATRT cells at virtually all therapeutic doses. These findings were consistent in cell lines that cover all three molecular subgroups of ATRTs.

CONCLUSIONS:

The results of this investigation have established that TG02 is an effective therapeutic against ATRTs in vitro. Given the lack of standard therapy for ATRTs, these findings help fill an unmet need and support further study of TG02 as a potential therapeutic option for patients with this deadly disease.

News (Medical) associated with Zotiraciclib

18 May 2022

·www.globenewswire.com

Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (“COF”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), has completed the patient enrollment for a Phase III, multicenter, randomized, double blinded, placebo-controlled clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (“ES-SCLC”). This clinical trial involves 54 centers and is led by Prof. Shun Lu (陸舜) from Shanghai Chest Hospital (上海市胸科醫院). The clinical trial approval was granted by China’s National Medical Products Administration (“NMPA”) on 1 March 2021, and the first patient was enrolled on 15 July 2021. A total of 498 patients have been enrolled into the study. An interim analysis is expected to be conducted in April 2023. Socazolimab is an in-licensed product from Sorrento for the People’s Republic of China, Hong Kong, Macau and Taiwan. To date, three Phase I clinical trials of Socazolimab monotherapy have been completed: (1) recurrent or metastatic cervical cancer; (2) advanced urothelial carcinoma; and (3) high-grade osteosarcoma after adjuvant chemotherapy for maintenance purpose. For recurrent or metastatic cervical cancer, a pivotal study has been completed and breakthrough therapy designation has been granted by the NMPA in February 2021, and a New Drug Application therefor was submitted to and accepted by the Center for Drug Evaluation of the NMPA for review in October 2021. Apart from monotherapies, several studies of Socazolimab combined with chemotherapy are being conducted in advanced urothelial carcinoma (Phase Ib), ES-SCLC (Phase III), neoadjuvant treatment in esophageal carcinoma (Phase Ib+II), metastatic melanoma (Phase Ib) and resected biliary tract cancer (Phase I). About Socazolimab Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB™ library platform. Socazolimab has the following potential advantages over its competitors: Fully human antibody potentially allows it to have minimal immunogenicity; demonstrated by its negative antigen-derived antibody (ADA) generation in humans in studies to date. Potentially lower dose required to achieve efficacy compared to other anti-PD-L1 antibodies. Dual mechanism of action observed with both immune-checkpoint inhibition and antibody-dependent cellular cytotoxicity (ADCC) effect. About ES-SCLC and Immunotherapy Atezolizumab, a PD-L1 inhibitor, in combination with carboplatin and etoposide, was approved by the NMPA as a first-line treatment for extensive-stage small cell lung cancer. The treatment was a major milestone and the first new treatment for the aggressive cancer in decades; it increased the median overall survival by 2 months and reduced the risk of death by 23% compared with chemotherapy alone in this disease setting. The advance was celebrated as a major milestone. Durvalumab, another PD-L1 inhibitor, has been granted the New Drug Approval (NDA) in ES-SCLC in China early this month. No PD-1 inhibitor has been approved in this indication. About China Oncology Focus Limited (COF) COF is a subsidiary of Lee’s Pharm and a clinical development stage company focused on oncology. COF is currently developing several assets, including Socazolimab (anti-PD-L1 antibody) in pivotal clinical trial stage; Zotiraciclib, an oral multi-kinase inhibitor in Phase I clinical trial for glioblastoma; Gimatecan, a topoisomerase I inhibitor for ovarian cancer; Pexa-vec (oncolytic virus) which is in global Phase Ib clinical trial for renal cell cancer. COF has built a pipeline of 10 assets through internal development and in-licensing. The diversity of its products creates a unique position for the company to use immune oncology as backbone therapy in combination with in-house products and develop potential paradigm-shifting treatment for cancer. About Lee’s Pharm Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information available at www.leespharm.com. About Sorrento Therapeutics, Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVISHIELD™ and COVI-MSC™; and diagnostic test solutions, including COVIMARK™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

AntibodyClinical ResultCollaborateBreakthrough TherapyFirst in ClassVaccine

25 Jan 2021

·www.pharmaceutical-technology.com

Adastra opens CRO pitches for Phase II trial of zotiraciclib

Adastra Pharmaceuticals welcomes CRO pitches for a Phase II trial of zotiraciclib in adults with recurrent high-grade gliomas and an isocitrate dehydrogenase (IDH) mutation, CEO Scott Megaffin said. In addition, the company has initiated a $45m Series B round to finance the study and other clinical trial development. The Princeton, New Jersey-based company aims to start the trial by 2Q21 with trial sites in both the US and Europe, Megaffin said. Adastra eyes a CRO with previous experience working with small molecules and conducting high-grade glioma trials, he added. The company would prefer a full-service CRO, with no specific preferences for CRO size or geographic location, he explained. Though the trial details will be based on upcoming regulatory conversations, the trial could enrol approximately 200–300 patients, Megaffin said. Adastra is considering overall survival and median progression-free survival (PFS) after 6 and 12 months as possible trial endpoints, as are consistent with industry standards, he noted. Previously, a Phase Ib trial measuring safety and efficacy of zotiraciclib with temozolomide in patients with recurrent high-grade gliomas found a stronger efficacy signal in the subset of patients with IDH-mutated tumours, Megaffin said. Currently, there are no trials focusing on this specific subpopulation, indicating a significant unmet need in the field, he added. The Phase Ib, which was conducted by the National Cancer Institute, met its PFS endpoint, according to topline results published in a 13 January company press release. Adastra plans to publish the full study results during ASCO in June, Megaffin said. To finance the upcoming Phase II trial, and to bring zotiraciclib to clinic in several other oncology indications with metastasis-initiating cells, Adastra is now initiating a Series B fundraising round, Megaffin said. The company hopes to close the round in 2Q21, shortly before it begins the Phase II, he explained. Currently, there is significant internal interest among a number of blue-chip venture capital firms and partners in China and Russia that have already invested in the company, Megaffin said. Adastra’s current investors include Domain Associates, Lee’s Pharma, Morgenthaler Private Equity, ProQuest, RusnanoMedInvest and Mitsubishi, according to the company website. Adastra will also open the round to outside private investors, though the company has not yet determined what specific types of investors it seeks, he added. An unspecified amount of current company funding will last up to the start of the Phase II trial, he explained. Zotiraciclib is a potent oral cyclin-dependent kinase 9 inhibitor that can cross the blood-brain barrier and deplete antiapoptotic oncogenes, according to the company website. William Newton is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData. Thematic Reports Are you worried about the pace of innovation in your industry? GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business. Find out more

Small molecular drugASCO

14 Jan 2021

·www.biospace.com

Adastra Pharmaceuticals, Inc. to Present at Inaugural B. Riley Securities' Oncology Investor Conference

PRINCETON, N.J., Jan. 14, 2021 /PRNewswire/ -- Adastra Pharmaceuticals Inc. (Adastra), a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced that Scott Megaffin, Chief Executive Officer, will present at the inaugural 2021 B. Riley Securities' Oncology Investor Conference, being held virtually January 20-21, 2021. Mr. Megaffin will present Adastra's corporate strategy and clinical plans for its lead candidate, Zotiraciclib, which is a potent, orally delivered, cyclin-dependent kinase 9 (CDK9) inhibitor that readily crosses the blood-brain barrier to treat cancers characterized by Myc overexpression. Adastra recently announced positive top-line results from a clinical trial of Zotiraciclib in the treatment of high-grade gliomas. The announcement can be accessed here. Presentation Details About Adastra Pharmaceuticals Adastra Pharmaceuticals Inc. is an innovative, private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Our vision is to identify, develop and deliver to patients important new therapies for diseases with significant unmet need. This commitment is epitomized by our lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). We invite you to learn more about Adastra, our clinical and scientific partners and our journey to bring meaningful new therapies to patients, by visiting . Ignacio Guerrero-Ros, Ph.D. Russo Partners, LLC (646) 942-5604 Ignacio.Guerrero-Ros@russopartnersllc.com David Melamed, Ph.D. Russo Partners, LLC (212) 845-4225 David.Melamed@russopartnersllc.com

First in Class

100 Deals associated with Zotiraciclib

External Link

KEGG	Wiki	ATC	Drug Bank
D11599	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma	Phase 2	US	National Cancer Institute	14 Dec 2016
Gliosarcoma	Phase 2	US	National Cancer Institute	14 Dec 2016
High grade glioma	Phase 2	-	Beijing Percans Oncology Co., Ltd.	-
Recurrent Glioma	Phase 1	CN	Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.	24 Apr 2019
Recurrent Malignant Glioma	Phase 1	CN	Lee's Pharmaceutical Holdings Ltd.	22 Mar 2019
Advanced Hepatocellular Carcinoma	Phase 1	-	Lee's Pharmaceutical Holdings Ltd.	01 Dec 2018
Chronic Lymphocytic Leukemia	Phase 1	US	Adastra Pharmaceuticals, Inc.	01 Sep 2012
Small Lymphocytic Lymphoma	Phase 1	US	Adastra Pharmaceuticals, Inc.	01 Sep 2012
Acute Lymphoblastic Leukemia	Phase 1	US	Adastra Pharmaceuticals, Inc.	01 Aug 2010
Acute Myeloid Leukemia	Phase 1	US	Adastra Pharmaceuticals, Inc.	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	Recurrent Glioblastoma	-	Zotiraciclib	ymuccytalc(vekbnvhhcf) = Main toxicities of zotiraciclib were gastrointestinal disorders zlkpynzpnl (esvyynyvdh ) View more	-	24 May 2024
NCT03224104 (STEAM, ASCO2023) Manual	Phase 1	Glioblastoma \| Recurrent Glioblastoma	71	Radiation Therapy+Zotiraciclib	oftawwdfjm(fmechpsbve) = wsqdmacwqp atxjludamm (gfizjjojij ) View more	Negative	26 May 2023
NCT03224104 (STEAM, ASCO2023) Manual	Phase 1	Glioblastoma \| Recurrent Glioblastoma	71	Temozolomide+Zotiraciclib	oftawwdfjm(fmechpsbve) = fnueycrsir atxjludamm (gfizjjojij ) View more	Negative	26 May 2023
NCT02933944 (CTgov)	Phase 1	Rectal Cancer	6	pembrolizumab+TG02-treatment	vpcjfybisu(bliawsxbnh) = pdaydexssd czmhiugiwl (dlzzifjkxw, umlrmhfyhr - xuapdqhohk) View more	-	26 Jan 2022
NCT02942264 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Astrocytoma	53	Zotiraciclib+Temozolomide	hsccywbiqy(azllkynkuu) = metibwzdqr xoggwxbued (loktelsetn ) View more	Positive	15 Jun 2021
AACR2014	Phase 1	Acute Myeloid Leukemia	-	TG02	wivqhkzhyw(vdyevqoxjw) = tznsjamxji gxoajwyipv (qswrrswpxp ) View more	-	01 Oct 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis